ArticleActa pharmaceutica Sinica. B2018
Efficacy of inverso isomer of CendR peptide on tumor tissue penetration.
Article in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- SARS-CoV-2 cell entry beyond the ACE2 receptor.Molecular biology reports · 2022Pooled it
- Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions.Pharmaceutics · 2025Review
- A synthetic peptide, derived from neurotoxin GsMTx4, acts as a non-opioid analgesic to alleviate mechanical and neuropathic pain through the TRPV4 channel.Acta pharmaceutica Sinica. B · 2025Article
- Size-transformable nanotherapeutics for cancer therapy.Acta pharmaceutica Sinica. B · 2025Review
- Deformable nanocarriers for enhanced drug delivery and cancer therapy.Exploration (Beijing, China) · 2024Review
- A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replication.Molecular therapy. Nucleic acids · 2024Article
- Topoisomeric Membrane-Active Peptides: A Review of the Last Two Decades.Pharmaceutics · 2023Review
- Recent advances in peptide-based therapeutic strategies for breast cancer treatment.Frontiers in pharmacology · 2023Review
- Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma.Signal transduction and targeted therapy · 2021Article
- Neuropilin 1 Regulation of Vascular Permeability Signaling.Biomolecules · 2021Review
- The Immunopathogenesis of Neuroinvasive Lesions of SARS-CoV-2 Infection in COVID-19 Patients.Frontiers in neurology · 2021Review
- Berberine prevents primary peritoneal adhesion and adhesion reformation by directly inhibiting TIMP-1.Acta pharmaceutica Sinica. B · 2020Article
- Targeting peptide-decorated biomimetic lipoproteins improve deep penetration and cancer cells accessibility in solid tumor.Acta pharmaceutica Sinica. B · 2020Article
- Size-Tunable Strategies for a Tumor Targeted Drug Delivery System.ACS central science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.